Introduction
Non-invasive molecular imaging offers great promise to assess response to conventional and molecularly targeted therapy [1] [2] [3] . Conventional methods to assess proliferation rely on random sampling of tissue by biopsy and subsequent histological assessment of proliferative markers. In addition to potential complications from biopsy, information gleaned by this analysis may be misleading because it does not reflect tissue heterogeneity. The positron emission tomography (PET) tracer 3 0 -deoxy-3 0 [ 18 F]-fluorothymidine ([ 18 F]FLT) is commonly used as an imaging biomarker of proliferation in oncology, especially for monitoring response in interventional studies [4] [5] [6] . [ 18 F]FLT is transported across cell membranes by nucleoside transporters and then phosphorylated by the enzyme thymidine kinase 1 (TK1). Following phosphorylation, [ 18 F]FLT-monophosphate is trapped and accumulates within the cell without being incorporated into DNA [7, 8] . TK1 is predominantly expressed during the DNA synthesis (S) phase of the cell cycle, but is virtually absent in quiescent cells, forming the basis of [ 18 F]FLT as a proliferation tracer [7] [8] [9] . Many groups have evaluated correlation between [ 18 F]FLT accumulation in proliferative tissues and cellular proliferation as assessed by immunohistochemical staining [7] , yet clinical evaluation of [ 18 F]FLT as a biomarker of proliferation in disease settings outside of oncology has not been reported.
Ménétrier's disease (MD) is a rare, hyperproliferative disorder of the stomach that has been linked to increased levels of the epidermal growth factor receptor (EGFR) ligand transforming growth factor alpha (TGF-a) and heightened EGFR activity in the gastric mucosa [10] [11] [12] [13] . This condition is thought to push differentiating epithelial cells of the gastric unit down the surface mucous cell (pit cell) lineage at the expense of the glandular (parietal and chief cell) lineage. In turn, the allocation of cells is shifted towards the pit such that the normal pit/gland ratio (1:4) is not observed and is frequently inverted. The resulting histological appearance is termed foveolar hyperplasia and is an essential characteristic of MD. Historically, gastrectomy has been considered the only effective treatment option until recent results illustrated the efficacious use of the EGFR neutralizing monoclonal antibody cetuximab [14] [15] [16] . A biomarker of response to cetuximab therapy as shown in these studies was reduced proliferation in stomach tissue as measured by Ki67 immunohistochemistry. We subsequently hypothesized that [ 
Materials and methods

Patients
All studies were approved by the Vanderbilt Institutional Review Board. Written informed consent was received from the patient prior to study enrollment. A 48-year old Caucasian female with MD was enrolled in a clinical trial investigating cetuximab for the treatment of refractory MD. The patient was treated with an initial loading dose of cetuximab (400 mg/m 2 ) at week 1, followed by additional treatments (250 mg/m 2 ) at weeks 2, 3, and 4. The patient continued with bi-monthly cetuximab treatments for a total of 15 months. [ 18 F]FLT uptake in a normal stomach was measured in a 47-year-old female with rectal cancer, but an otherwise normal stomach. This patient was enrolled in an unrelated study of patients with colorectal cancer.
Gastric biopsy
Pinch biopsies of the gastric fundus in the MD patient were performed at multiple time points throughout the study (1 day before treatment, 1 day after treatment, 1 month after treatment, 15 months after treatment). Samples were fixed in buffered formalin overnight and then transferred to 70 % ethanol prior to immunohistochemical analysis. Radiopharmaceutical synthesis
0 -deoxythymidine) was prepared as described previously [17, 18] . [ 18 F]FLT was obtained with average radiochemical purity of 98.3 % and specific activity of 128.76 TBq/mmol.
Imaging study protocol
Patients received an intravenous injection of 185 MBq of [ 18 F]FLT and then rested for 60 min before imaging. Immediately prior to imaging, the MD patient was administered an oral contrast agent (VoLumen TM , Bracco Diagnostics, Inc.). Imaging was performed with an integrated PET/CT scanner (Discovery LS, GE Healthcare), consisting of a combined full-ring PET scanner (Advance NXi) and an eight-section helical CT scanner (Light Speed Plus). The PET/CT scan was performed from the lower chest to the iliac crests. The CT was performed with 140 kV, 80 mA, a tube-rotation time of 0.8 s per rotation, a pitch of 1.675 mm/rotation, with CT slice thickness of 3.75 mm at intervals of 3.27 mm and a matrix of 512 9 512 pixels. The CT data were reconstructed with a slice thickness of 5.0 mm and a matrix of 512 9 512 pixels. Patients were allowed normal, quiet breathing during imaging. PET imaging was performed with 5 min per table position with two positions acquired. PET data sets were reconstructed iteratively using the ordered subsets expectation maximization (OSEM) algorithm with segmented attenuation correction (two iterations). PET images were up-interpolated by vendor-provided software to match the CT matrix for image fusion. Independent as well as coregistered images were displayed using a vendor provided workstation (Xeleris; GE Medical Systems). As there is no focal lesion in MD, the maximum standardized uptake value (SUV max ) was determined across the entire stomach. The rugal fold thickness along the greater curve of the stomach was measured using the CT images.
Histological validation
Biopsy samples of the gastric fundus were blocked in paraffin and sectioned prior to immunostaining for proliferation markers including Ki67 (G1 through M-phase marker), proliferating cell nuclear antigen (PCNA, S-phase marker), DNA replication licensing factor MCM6 (MCM6, early G1 through M-phase marker), and p-Histone H3 (Mphase marker), as well as with periodic-acid Schiff (PAS) stain. Serial sections were incubated with primary monoclonal antibodies for Ki67 (Dako #M7240, 1:100 dilution), PCNA (Biomeda #V1006, 1:1000 dilution), MCM6 (Santa Cruz #sc-9843, 1:1000 dilution) or p-Histone H3 (Cell Signaling #9701, 1:100 dilution). PAS-stained samples were incubated with 0.5 % periodic acid followed by Schiff reagent, and then counterstained with hematoxylin. Stained samples were imaged at high magnification and analyzed by a gastrointestinal pathologist (MKW). The proliferative index for each marker was expressed as the average number of positive cells per gland based on counting at least 10 well-oriented glands per sample.
Results
PET/CT imaging
Consistent with previous findings in MD patients [10] , abdominal CT images collected 1 day prior to administration of cetuximab revealed enlargement of rugal folds throughout the stomach ( Fig. 1a; Table 1 ). Subsequent [ 18 F]FLT-PET images revealed the physiological distribution of the tracer in normal liver and bone marrow, as well as significant, focal uptake in stomach tissue (SUV max 5.3; Fig. 1b) . Within the stomach itself, tracer accumulation was highest in the fundus and antrum and somewhat less along the greater curvature. Following the imaging session, the patient was administered cetuximab and returned for imaging 24 h following treatment. One day following the initial treatment with cetuximab, no significant changes were observed in stomach distention or rugal fold thickness by CT imaging (Fig. 1c) . However, there was significantly reduced [ 18 F]FLT-PET tracer uptake throughout the stomach (SUV max 1.6; Fig. 1d ). Reduced [
18 F]FLT uptake was also observed after 1 month of treatment (SUV max 2.3; Fig. 1f ) and after 15 months of treatment (SUV max 2.4; Fig. 1h ). Compared to 1 day post-treatment, [ 18 F]FLT-PET at 1 month and 15 months was modestly increased and appeared to correlate with remodeling of the gastric mucosa and a return to normal pathology. At 1 month, we did not observe significant changes in stomach distention or rugal fold thickness (Fig. 1e) . However, stomach distention and rugal fold thickness were both markedly reduced at 15 months (Fig. 1g) .
In the patient presenting with a normal stomach, CT imaging of the stomach was unremarkable with a normal fasting appearance with normal appearing mucosa and gastric wall (Fig. 2a) Fig. 2b ; Table 1 ) as well as characteristic uptake in the liver and bone marrow.
Histology
Prior to treatment, histological samples from the MD patient revealed significant foveolar hyperplasia, with marked thickening of the gastric mucosa and an inverted pit/gland ratio (Fig. 3 ), which were both distinct from normal stomach tissue (Table 1) . Gastric biopsy samples in MD showed elevated levels of proliferation markers Ki67, PCNA, MCM6, and p-Histone H3 (Fig. 4 18 F]FLT-PET than Ki67 or MCM6 when comparing pre-treatment levels with measurements taken at steady-state cetuximab levels (e.g., 1 month and 15 months post-treatment). Histological normalization of stomach architecture, with near complete resolution of foveolar hyperplasia, decreased thickness of the gastric mucosa, and decreased pit/gland ratio was observed at 15 months post-treatment ( Fig. 3; Table 1 ).
Discussion
To our knowledge, this study reports the first clinical use of [ 18 F]FLT-PET to assess proliferation in a non-malignant disorder. This study suggests that pharmacodynamic response to EGFR blockade and clinical resolution of MD can be predicted by [ 18 F]FLT-PET. This finding is not unexpected, given that EGFR inhibition and attendant downstream mitogen-activated protein kinase (MAPK) pathway inhibition can result in reduced cellular proliferation in a cyclin D1-CDK4/6-pRb-E2F-TK1 dependent fashion [19] . Signaling cascades involved in MD are incompletely described, although it has been suggested that downstream signaling in MD could proceed through EGFR-HER3 heterodimeric activation of the phosphatidylinositol 3-kinase (PI3K) pathway [10] . Activation of show a gradual normalization of pit structure and a resolution of foveolar hyperplasia. d At 15 months post-therapy, the stomach has returned to a more histologically normal appearance, with shallow pits (arrow) and a normal pit/gland ratio PI3K can affect cell cycle in complex ways including targeted degradation of cell cycle inhibitors (e.g., p27) and mammalian target of rapamycin (mTOR)-mediated activation of pro-translational molecules at the ribosomal cap (e.g., eIF4E) [15] . Importantly for early prediction of response associated with pharmacodynamic target inhibition, reduced [ 18 F]FLT uptake was observed as early as 24 h following initiation of cetuximab therapy, somewhat earlier than a portion of the tissue-based markers evaluated in this study. Post-treatment [
18 F]FLT-PET collected 1 day following the first administration of cetuximab predicted the ultimate resolution of foveolar hyperplasia and normalization of the gastric architecture in this patient. PET also correlated, albeit to varying degrees, with proliferative indices measured throughout the treatment cycle. At the conclusion of therapy (15 months), the patient was asymptomatic and exhibited a nearly histologically normal gastric fundus. At this time, [ 18 F]FLT uptake was reduced by 56 % from measurements prior to cetuximab therapy. Over the course of therapy, [ 18 F]FLT-PET was able to provide a more sensitive and global assessment of MD in this patient compared to random biopsy alone.
Conclusion
This study suggests that [ 18 F]FLT-PET may improve therapeutic management of patients with MD and accelerate clinical development of therapeutic approaches for these patients and potentially other premalignant, hyperproliferative disorders. Following initiation of treatment, samples begin to exhibit normalization of the gastric architecture. By 15 months, levels of all proliferation markers are significantly decreased from pre-treatment levels. Corresponding tissue samples are shown for normal stomach tissue. Quantitative results can be seen in Table 1 
